Andere Sprachen Poolbeg Pharma PLC

Aktien

A3CVN5

GB00BKPG7Z60

POLB

Markt geschlossen - London S.E. Andere Börsenplätze 17:35:14 31.05.2024			% 5 Tage	% 1. Jan.
13,7 ^GBX	+4,58 %		+4,58 %	+51,38 %

01.05.	Poolbeg Pharma erhält vollständiges US-Patent für Immunomodulator II	MT
01.05.	Poolbeg Pharma feiert die vollständige Patenterteilung für Immunomodulator II	AN

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	01.05.
Poolbeg Pharma celebrates full patent approval for Immunomodulator II	01.05.
Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application	01.05.
Poolbeg Pharma Signs Option Deal to Buy Orphan Drug Candidate from Silk Road Therapeutics	30.04.
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	30.04.
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	20.03.
Poolbeg Pharma plc Announces POLB 001 US Patent Update	20.03.
Diversified Energy offers dividend alternative	15.02.
Poolbeg Pharma's Nonexecutive Chair Transitions to Executive Role	15.02.
Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman	15.02.
Katoro Gold launches fundraising, eyes board shake-up	12.02.
Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome	12.02.
Poolbeg Pharma Therapy Shows Efficacy in Lowering Cancer Immunotherapy-induced Cytokine Release Syndrome	17.01.
Poolbeg Pharma hails POLB 001'S potential to treat CRS	17.01.
Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome	17.01.
K3 Business says cash balances ahead of forecast	20.12.
Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully	20.12.
Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001	11.12.
Poolbeg Pharma plc Announces Directorate Changes	30.11.
Poolbeg hails approval; EDX links with Thermo Fisher	21.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Poolbeg Pharma PLC

Aktien

A3CVN5

GB00BKPG7Z60

POLB

Andere Sprachen

Filter